Difference between revisions of "Alpelisib (Piqray)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Created page with "==Mechanism of action== From [http://www.cancer.gov/publications/dictionaries/cancer-drug?CdrID=718963 NCI Drug Dictionary]: An orally bioavailable phosphatidylinositol 3-kina...")
 
Line 9: Line 9:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
*5/24/2019: Approved in combination with fulvestrant for postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, [[Breast cancer, PIK3CA-mutated|PIK3CA-mutated, advanced or metastatic breast cancer]] as detected by an FDA-approved test following progression on or after an endocrine-based regimen.  
+
*5/24/2019: Approved in combination with fulvestrant for postmenopausal women, and men, with [[Biomarkers#HR|hormone receptor (HR)]]-[[Biomarkers#Expression|positive]], [[Biomarkers#HER2|human epidermal growth factor receptor 2 (HER2)]]-[[Biomarkers#Normal_expression|negative]], [[Biomarkers#PIK3CA|PIK3CA]]-[[Biomarkers#SNV|mutated]], advanced or metastatic [[breast cancer]] as detected by an FDA-approved test following progression on or after an endocrine-based regimen.
  
 
==Also known as==
 
==Also known as==

Revision as of 05:11, 10 January 2020

Mechanism of action

From NCI Drug Dictionary: An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.

Diseases for which it is used

Patient drug information

To be completed

History of changes in FDA indication

Also known as

  • Code name: BYL719
  • Brand name: Piqray

References